Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Immunology
Volume 2018, Article ID 4520294, 8 pages
https://doi.org/10.1155/2018/4520294
Case Report

Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy

1Beaumont Hospital, Oakland University School of Medicine, Department of Hematology and Oncology, Royal Oak, MI, USA
2Beaumont Hospital, Oakland University School of Medicine, Department of Anatomic and Hematopathology, Royal Oak, MI, USA
3Beaumont Hospital, Oakland University School of Medicine, Department of Diagnostic Radiology and Molecular Imaging, Royal Oak, MI, USA

Correspondence should be addressed to Bolanle Gbadamosi; ude.tnomuaeb@isomadabg.elnalob

Received 10 October 2017; Accepted 27 December 2017; Published 12 February 2018

Academic Editor: Rajni Rani

Copyright © 2018 Bolanle Gbadamosi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Cancer Facts and Figures 2017. American Cancer Society. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html.
  2. S. M. De la Monte, G. W. Moore, and G. M. Hutchins, “Patterned distribution of metastases from malignant melanoma in humans,” Cancer Research, vol. 43, no. 7, pp. 3427–3433, 1983. View at Google Scholar
  3. M. A. Nelson, M. D. Radmacher, R. Simon et al., “Chromosome abnormalities in malignant melanoma: Clinical significance of nonrandom chromosome abnormalities in 206 cases,” Cancer Genetics and Cytogenetics, vol. 122, no. 2, pp. 101–109, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Larkin, F. S. Hodi, and J. D. Wolchok, “Combined nivolumab and ipilimumab or monotherapy in untreated melanoma,” The New England Journal of Medicine, vol. 373, no. 13, p. 1270, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. JD. Battle and J. Stasney, “Malignant melanoma cells in the bone marrow,” Archives of pathology, vol. 31, no. 5, pp. 631–633, 1941. View at Google Scholar
  6. M. A. Rubinstein, “Malignant melanoma diagnosed by marrow aspiration,” Acta Haematologica, vol. 2, no. 4, pp. 234–237, 1949. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Franklin, D. C. Zavala, and C. E. Radcliffe, “The detection of malignant melanoma by bone marrow aspiration; a report of two cases,” Blood, vol. 7, no. 9, pp. 934–941, 1952. View at Google Scholar · View at Scopus
  8. D. Brown, M. Boniuk, and R. L. Font, “Diffuse malignant melanoma of iris with metastases,” Survey of Ophthalmology, vol. 34, no. 5, pp. 357–364, 1990. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Basile, B. Moskowitz, J. Harris, N. Blumberg, and J. M. Bennett, “Malignant melanoma: Primary presentation in bone marrow and lymph node,” Medical and Pediatric Oncology, vol. 20, no. 1, pp. 75–77, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Villarrubia, R. F. de Misa, L. Escribano, C. Bellas, and J. L. Velasco, “Amelanotic Bone Marrow Infiltration Secondary to Pigmented Malignant Melanoma,” The Journal of Dermatology, vol. 22, no. 8, pp. 620–622, 1995. View at Publisher · View at Google Scholar
  11. R. Invernizzi and A. Pecci, “A case of metastatic malignant melanoma with bone marrow involvement,” Haematologica, vol. 86, no. 4, p. 447, 2001. View at Google Scholar · View at Scopus
  12. C. S. Chim and N. J. Trendell Smith, “Primary malignant ocular melanoma: A bone marrow diagnosis,” British Journal of Haematology, vol. 112, no. 1, p. 2, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Basu, B. A. Bhade et al., “Malignant melanoma metastatic to bone marrow,” Indian Journal of Pathology and Microbiology, vol. 45, no. 1, pp. 107–109, 2002. View at Google Scholar
  14. J. A. Batsis and M. J. Barry, “Metastatic malignant melanoma presenting with hypercalcaemia and bone marrow involvement,” Journal of the European Academy of Dermatology and Venereology, vol. 20, no. 4, pp. 432–434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Uesawa, K. Sato, K. Ozaki, T. Nagai, K. Muroi, and K. Ozawa, “Bone marrow metastasis of malignant melanoma,” Internal Medicine, vol. 45, no. 5, p. 341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Jain, T. Singh, N. Kumar, and M. K. Daga, “Metastatic malignant melanoma in bone marrow with occult primary site - A case report with review of literature,” Diagnostic Pathology, vol. 2, no. 1, article no. 38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Bhandari, F. Jack, K. Hussain, and A. Bell, “Metastatic melanoma in the marrow: A black and white diagnosis: Images in haematology,” British Journal of Haematology, vol. 147, no. 1, p. 1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Downing, C. Pitchford, and M. Royer, “Malignant melanoma presenting as lytic skeletal lesions and bone marrow infiltration,” The American Journal of Dermatopathology, vol. 34, no. 5, 2012. View at Google Scholar
  19. S.-Y. Hsiao and T.-Y. Chen, “Uveal melanoma with diffuse bone marrow involvement,” Blood, vol. 124, no. 12, p. 1996, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Suzuki, S. Kusumoto, S. Iida, T. Tada, and F. Mori, “Amelanotic malignant melanoma of unknown primary origin metastasizing to the bone marrow: A case report and review of the literature,” Internal Medicine, vol. 53, no. 4, pp. 325–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Bertolotti, H. Conte, E. Amazan et al., “Metastatic melanoma with leukaemia-like evolution,” Acta Dermato-Venereologica, vol. 93, no. 6, pp. 729-730, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Velasco-Rodríguez, M. Castellanos-González, J. M. Alonso-Domínguez, M. Martín-González, and J. Villarrubia, “Metastatic malignant melanoma detected on bone marrow aspiration,” British Journal of Haematology, vol. 162, no. 4, pp. 432–432, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Serrier and J.-F. Lesesve, “Metastatic malignant melanoma in the bone marrow,” Blood, vol. 121, no. 5, p. 721, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Ferla, A. Freyrie, F. Guidotti, E. Bonoldi, U. Gianelli, and A. Cortelezzi, “Bone marrow localisation of metastatic melanoma and synchronous leukaemic evolution of low-risk myelodysplastic syndrome,” Journal of Clinical Pathology, vol. 66, no. 1, pp. 75–78, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Mirfazaelian, A. Rezvani, and Y. Daneshbod, “Black bone marrow aspirate,” Journal of Postgraduate Medicine, vol. 59, no. 3, pp. 246–248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Kalodimos, P. Skoufogiannis, S. Lafioniatis, V. Pappi, P. Fanourgiakis, and A.-M. Feritsean, “Metastatic melanoma in bone marrow, report of a rare case,” Virchows Arch, vol. 469, S1-S346 PS-15-018, no. 1, 2016. View at Google Scholar
  27. J. Volejnikova, V. Bajciova, L. Sulovska et al., “Bone marrow metastasis of malignant melanoma in childhood arising within a congenital melanocytic nevus,” Biomedical Papers, vol. 160, no. 3, pp. 456–460, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Kassam and C. Shah, “Amelanotic melanoma in the bone marrow,” Blood, vol. 128, no. 2, p. 313, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Fukumoto, M. Sakaguchi, M. Oka, M. Nishimura, T. Mukohara, and C. Nishigori, “Malignant melanoma with bone marrow involvement diagnosed from hypercalcemia: Development of a neural cell adhesion molecule stain,” The Journal of Dermatology, vol. 44, no. 5, pp. e105–e106, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Rosner, F. Sen, and M. Postow, “Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone,” Journal for ImmunoTherapy of Cancer, vol. 5, no. 1, 2017. View at Publisher · View at Google Scholar
  31. N. Baniak, M. Podberezin, S. C. Kanthan, and R. Kanthan, “Primary pulmonary/pleural melanoma in a 13 year-old presenting as pleural effusion,” Pathology - Research and Practice, vol. 213, no. 2, pp. 161–164, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Kilickap, M. Erman, M. Dincer, H. Harputluoglu, and S. Yalcin, “Bone marrow metastasis of solid tumors: Clinicopathological evaluation of 73 cases,” Turkish Journal of Cancer, vol. 37, no. 3, pp. 085–088, 2007. View at Google Scholar
  33. R. A. Savage, F. V. Lucas, and G. C. Hoffman, “Melanoma in marrow aspirates.,” American Journal of Clinical Pathology, vol. 79, no. 2, pp. 268-269, 1983. View at Publisher · View at Google Scholar · View at Scopus
  34. G. H. Baab and C. M. McBride, “Malignant melanoma: the patient with an unknown site of primary origin,” JAMA Surgery, vol. 110, no. 8, pp. 896–900, 1975. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Bakalian, J.-C. Marshall, P. Logan et al., “Molecular pathways mediating liver metastasis in patients with uveal melanoma,” Clinical Cancer Research, vol. 14, no. 4, pp. 951–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. T. J. Hieken, S. G. Ronan, M. Farolan, A. L. Shilkaitis, and T. K. Das Gupta, “Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma,” Cancer, vol. 85, no. 2, pp. 375–382, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. T. J. Hieken, S. G. Ronan, M. Farolan, A. L. Shilkaitis, and T. K. Das Gupta, “β1 integrin expression: A marker of lymphatic metastases in cutaneous malignant melanoma,” Anticancer Reseach, vol. 16, no. 4 B, pp. 2321–2324, 1996. View at Google Scholar · View at Scopus
  38. R. N. Kaplan, S. Rafii, and D. Lyden, “Preparing the “soil”: the premetastatic niche,” Cancer Research, vol. 66, no. 23, pp. 11089–11093, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Huncharek, J. F. Caubet, and R. McGarry, “Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials,” Melanoma Research, vol. 11, no. 1, pp. 75–81, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. P. B. Chapman, L. H. Einhorn, M. L. Meyers et al., “Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2745–2751, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. M. R. Middleton, J. J. Grob, N. Aaronson et al., “Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 158–166, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. F. O. Smith, S. G. Downey, J. A. Klapper et al., “Treatment of metastatic melanoma using Interleukin-2 alone or in conjunction with vaccines,” Clinical Cancer Research, vol. 14, no. 17, pp. 5610–5618, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. B. Atkins, M. T. Lotze, and J. P. Dutcher, “High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2105–2116, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. D. L. Morton and A. Barth, “Vaccine therapy for malignant melanoma,” CA: A Cancer Journal for Clinicians, vol. 46, no. 4, pp. 225–244, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. M. S. Mitchell, W. Harel, and S. Groshen, “Association of HLA phenotype with response to active specific immunotherapy of melanoma,” Journal of Clinical Oncology, vol. 10, no. 7, pp. 1158–1164, 1992. View at Publisher · View at Google Scholar · View at Scopus
  46. M. S. Mitchell and D. J. Rechtman, “A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma,” Canadian Journal of Infectious Diseases and Medical, vol. 6, (Suppl C) 347C, 1995. View at Google Scholar
  47. C. Robert, L. Thomas, and I. Bondarenko, “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Hamid, C. Robert, A. Daud et al., “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 134–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. D. M. Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” Nature Reviews Cancer, vol. 12, no. 4, pp. 252–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Robert, J. Schachter, G. V. Long et al., “Pembrolizumab versus ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 372, no. 26, pp. 2521–2532, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. J. D. Wolchok, H. Kluger, and M. K. Callahan, “Nivolumab plus Ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 122–133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. J. D. Wolchok, V. Chiarion-Sileni, R. Gonzalez et al., “Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma,” The New England Journal of Medicine, vol. 377, no. 14, pp. 1345–1356, 2017. View at Publisher · View at Google Scholar
  53. L. Zimmer, S. Apuri, Z. Eroglu et al., “Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma,” European Journal of Cancer, vol. 75, pp. 47–55, 2017. View at Publisher · View at Google Scholar · View at Scopus
  54. J. S. Weber, S. P. D'Angelo, D. Minor et al., “Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial,” The Lancet Oncology, vol. 16, no. 4, pp. 375–384, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Google Scholar
  56. J. A. Sosman, K. B. Kim, L. Schuchter et al., “Survival in braf V600–mutant advanced melanoma treated with vemurafenib,” The New England Journal of Medicine, vol. 366, no. 8, pp. 707–714, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. G. V. Long, D. Stroyakovskiy, H. Gogas et al., “Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial,” The Lancet, vol. 386, no. 9992, pp. 444–451, 2015. View at Publisher · View at Google Scholar · View at Scopus